Ramin Farzaneh-Far

Ramin Farzaneh-Far is a Venture Partner at RA Capital where he works closely with RA’s Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs.
He was Chief Medical Officer of Ra Pharmaceuticals from 2016 until it was acquired by UCB in 2020.
Ramin is an experienced clinical trialist and previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences.
A trained cardiologist, he has held academic faculty positions at the University of California, San Francisco (UCSF) and the University of Texas Southwestern Medical Center.
Ramin completed his internal medicine residency at Brigham & Women’s Hospital in Boston and trained in cardiovascular medicine at UCSF.
He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF.